EZH2: biology, disease, and structure-based drug discovery
about
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisEZH2 in Bladder Cancer, a Promising Therapeutic TargetEpigenome-based personalized medicine in human cancerDietary Flavones as Dual Inhibitors of DNA Methyltransferases and Histone MethyltransferasesWeaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In VitroThe prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapyFunctional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.Could lncRNAs be the missing links in control of mesenchymal stem cell differentiation?Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4.Product binding enforces the genomic specificity of a yeast polycomb repressive complex.Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2.STAT3-driven transcription depends upon the dimethylation of K49 by EZH2.Histone methylases as novel drug targets: developing inhibitors of EZH2.High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast CancerThe Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine FibroidsThe inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway.EZH2: an emerging role in melanoma biology and strategies for targeted therapy.Histone lysine methylation in diabetic nephropathy.In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.Asxl1 deficiency in embryonic fibroblasts leads to cellular senescence via impairment of the AKT-E2F pathway and Ezh2 inactivation.Long noncoding RNAs in hepatitis B virus-related hepatocellular carcinoma.Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A.Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation.Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathyS-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cellsStructure of the PRC2 complex and application to drug discovery.Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids.EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells.The role of enhancer of zeste homologue 2 inhibitors in controlling epigenetics and their potential for cancer treatment.Expression of EZH2 in uveal melanomas patients and associations with prognosis.A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.Ezh2 promotes clock function and hematopoiesis independent of histone methyltransferase activity in zebrafish.Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells.Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns.
P2860
Q27853296-A8DA9252-159C-4D59-A4A7-8D816E0F4A1AQ28082054-31B5E324-ADE8-439E-ABAB-89BFC44CCEB2Q28083951-2E420A4B-70C2-48E8-BEBB-B75DEB7069CBQ28554315-D825B748-44C0-426F-886B-D291D06609B7Q29147503-D6C2CADE-6DF8-4DF0-B17E-46959C85CB4DQ34175876-9E11DE06-9204-4DF1-8240-5C86C5ABDFD7Q34469971-2B26BE9E-FEF3-4B1D-B225-80FD0EA62315Q34584549-DD382FD9-2BA9-486F-A00B-C7EBE7FDA3FCQ34982573-D35553E1-169F-4454-B272-B50CE211E86EQ35002456-3C521B1E-7E69-4ACD-9883-7947DA2383D7Q35228394-6C4A68E2-D5A0-4998-9368-31062D202CC6Q35279528-4589D0D7-7864-4BC8-8DB6-F8C90FF88C35Q35510392-4948A472-8B9C-4FCB-9E56-111753A8D373Q36768995-684042DE-3C3C-4232-8EC6-F26C36EB7EA4Q36791100-2651D447-B6DE-45D1-85EF-5AD4745A0A82Q37188911-DFB784C4-B2C1-41AC-BD48-45B2AEA2C3DBQ38218836-88637A9E-047F-4630-BA5B-6B8CDEB55A17Q38248614-CF04E7BB-BA35-455B-95F2-C66F6FE40960Q38388649-7A05AC18-2357-4AED-B9AA-C3134800EB52Q38401146-4A548C59-CE2E-4F83-8193-85FB73DBDA09Q38461519-570BCF25-E82A-4C2B-B824-04F58D5DB30CQ38567366-5B9CDD4F-6C0C-4220-BCE6-944FE6B48C48Q38707876-9ED24E6F-52F0-4C2F-A5F2-78D9E57EA1CFQ38792331-D34F01B4-39A0-4A81-9133-20C1A8CCE036Q38878459-71904400-819D-4BAF-968A-F0E8D6B7198BQ38885853-24D5F066-E80C-4C92-B9F2-15BFABF5EDCAQ38958182-A2648DFE-0FB5-406C-B8DA-A91AA5FCD1ECQ39245946-00B66B74-8B5C-47F2-8B87-8E0E6EE633C9Q39870818-3E90DA95-15A4-49F9-B82C-CCC79EA4EFCCQ40970939-9DB174A2-5260-45F6-8176-E3C66CF7298AQ43148207-C5731AB1-EFE2-4C3B-B4C6-8C9822005762Q44045703-70FADB9E-9B3D-4371-9E66-A11669D355C8Q45864008-47F38ABF-905B-49EE-A3BE-41215FBB769BQ46732136-FF390005-A25E-434B-BA9D-CEED251E76F9Q48675669-1444C1E6-FC5C-4BFB-86BB-50261B7C7BBCQ49977670-DF7ACB02-FBE1-44B1-8A4A-5F38946C7528Q52313298-985A9F1E-F859-4485-AF47-E7138E387CE8Q52369573-A79221B5-C70C-46DE-8EE4-DFDB9F333896Q54188074-4849604A-5A85-4A84-9BAE-3B5BF744F612Q54777296-BDD9AFA1-873C-4477-8B5D-66064C7719C9
P2860
EZH2: biology, disease, and structure-based drug discovery
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
EZH2: biology, disease, and structure-based drug discovery
@ast
EZH2: biology, disease, and structure-based drug discovery
@en
EZH2: biology, disease, and structure-based drug discovery
@nl
type
label
EZH2: biology, disease, and structure-based drug discovery
@ast
EZH2: biology, disease, and structure-based drug discovery
@en
EZH2: biology, disease, and structure-based drug discovery
@nl
prefLabel
EZH2: biology, disease, and structure-based drug discovery
@ast
EZH2: biology, disease, and structure-based drug discovery
@en
EZH2: biology, disease, and structure-based drug discovery
@nl
P2093
P2860
P921
P356
P1476
EZH2: biology, disease, and structure-based drug discovery
@en
P2093
P2860
P2888
P304
P356
10.1038/APS.2013.161
P577
2013-12-23T00:00:00Z
2014-02-01T00:00:00Z
P5875
P6179
1006403132